<unk>  has been studied in around 1,800 patients in two double-blind, randomized and controlled Phase-3 trials, titled reSURFACE 1 and reSURFACE 2, followed by a 4-year extension period. In the reSURFACE trials, a significantly higher proportion of patients receiving<unk>  achieved PASI 75 response at week 12 and a PGA score of “clear” or “minimal”, with at least a 2-grade reduction from baseline at week 12, than those in the placebo group (p<0.0001). Response continued to increase up to week 28 and was maintained through week 52.<unk>  was also proven to have superior efficacy to etanercept, an effective anti-TNFα treatment for psoriasis, with a significantly higher proportion of patients achieving PASI 75 and PASI 90 at weeks 12 and 28. After 3 years of continued treatment with<unk> , response levels were well maintained in week 28 responders: approximately 68% of patients maintained PASI 90 response and 91.6%, 79.8% and 51.9% maintained an absolute PASI of <5, <3, and <1, respectively (observed-cases data).
Tildrakizumab
Brolucizumab
Risankizumab
Mogamulizumab
Etaracizumab
Caplacizumab
Ixekizumab
Crizanlizumab